Huanopril

Huanopril

lisinopril

Manufacturer:

Zhejiang Huahai

Distributor:

Khriz Pharma
Concise Prescribing Info
Contents
Lisinopril dihydrate
Indications/Uses
HTN in adults & ped patients ≥6 yr; to reduce signs & symptoms of systolic heart failure; reduction of mortality in hemodynamically stable patients w/in 24 hr of acute MI.
Dosage/Direction for Use
HTN Adult Initially 10 mg once daily. Usual dosage range: 20-40 mg daily in a single dose. Patients taking diuretics Initially 5 mg once daily. Childn 6 ≥yr w/ GFR >30 mL/min/1.73 m2 Initially 0.07 mg/kg (up to 5 mg total) once daily. Heart failure Initially 5 mg once daily when used w/ diuretics & (usually) digitalis as adjunctive therapy for systolic heart failure. Patients w/ hyponatremia (serum Na <130 mEq/L) Initially 2.5 mg once daily. Max: 40 mg once daily as tolerated. Reduction of mortality in acute MI 5 mg in hemodynamically stable patients w/in 24 hr of the onset of symptoms of MI, followed by 5 mg after 24 hr, 10 mg after 48 hr & then 10 mg once daily continued for at least 6 wk. Patients w/ low systolic BP (≤120 mmHg & >100 mmHg) Initially 2.5 mg during the 1st 3 days after infarct. 5 mg daily maintenance dose may be given w/ temporary reductions to 2.5 mg as needed if hypotension occurs (systolic BP ≤100 mmHg). Renal impairment CrCl ≥10 mL/min & ≤30 mL/min ½ the usual initial dose, up titrate as tolerated to max of 40 mg daily, CrCl <10 mL/min or patients on hemodialysis Initially 2.5 mg once daily.
Administration
May be taken with or without food.
Contraindications
History of angioedema or hypersensitivity related to previous treatment w/ ACE inhibitor; hereditary or idiopathic angioedema. Do not administer w/in 36 hr of switching to or from sacubitril/valsartan. Do not co-administer w/ aliskiren in patients w/ diabetes. Combination w/ neprilysin inhibitor (eg, sacubitril).
Special Precautions
Patient w/ history of angioedema unrelated to ACE inhibitor therapy; discontinue & monitor if signs & symptoms of angioedema has occurred. Head, neck & intestinal angioedema. Sudden & potentially life threatening anaphylactoid reactions in patients dialyzed w/ high-flux membranes or undergoing LDL apheresis w/ dextran sulfate absorption. Risk of developing acute renal failure in patients whose renal function may depend in the activity of renin-angiotensin system (eg, renal artery stenosis, CKD, severe CHF, post-MI or vol depletion); w/hold or discontinue therapy in patients who develop a clinically significant decrease in renal function. Risk of excessive hypotension in patients w/ heart failure w/ systolic BP <100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe vol &/or salt depletion of any etiology; severe aortic stenosis or hypertrophic cardiomyopathy. Avoid use in patients who are hemodynamically unstable after acute MI. Hyperkalemia. Discontinue in patients who develop jaundice or marked elevations of hepatic enzymes. Concomitant use w/ mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitor. Periodically monitor renal function & serum K. Black patients. Renal impairment (CrCl ≤30 mL/min). Discontinue immediately when pregnancy is detected. Do not breastfeed during treatment. Not recommended in childn <6 yr or w/ GFR <30 mL/min/1.73 m2. Fetal toxicity. Elderly.
Adverse Reactions
Dizziness; hypotension. HTN: Headache, cough. Heart failure: Chest pain. Increased creatinine, hyperkalemia, syncope. Acute MI: Renal dysfunction.
Drug Interactions
Attenuated K loss w/ thiazide diuretics. Increased risk of hyperkalemia w/ K-sparing diuretics (spironolactone, amiloride, triamterene). Increased blood-glucose-lowering effect & risk of hypoglycemia w/ antidiabetic medicines (insulins, oral hypoglycemic agents). Deterioration of renal function & attenuated antihypertensive effect w/ NSAIDs, including selective COX-2 inhibitors. Increased risks of hypotension, hyperkalemia, & changes in renal function w/ dual blockade of the RAS by ARBs, ACE inhibitors, or aliskiren. Toxicity w/ lithium. Nitritoid reactions (facial flushing, nausea, vomiting & hypotension) w/ injectable gold (Na aurothiomalate). Increased risk for angioedema w/ mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus) & neprilysin inhibitor.
MIMS Class
ACE Inhibitors/Direct Renin Inhibitors
ATC Classification
C09AA03 - lisinopril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Huanopril tab 10 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in